This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.—
The interesting article "Digoxin-Prescribing: Mostly Good News" by Weintraub et al (242:445, 1979) seems marred by what appears to be an overemphasis on the brand name product of the drug company that sponsored the study. Opinions concerning the complex medical and political issues regarding generic prescribing and bioavailability of "equivalent" drugs should, in our minds, be well separated in scientific publications from important research data about physician-prescribing habits.It is our opinion that the use of generic products made by reputable firms is acceptable practice. (Physicians must work with local pharmacists to ensure that only such products are offered to patients.) In the particular case of digoxin, careful monitoring of clinical response combined with appropriate use of blood levels is essential, regardless of the drug's manufacturer.
Carter WH, Tarshis G. Digoxin Prescribing. JAMA. 1980;243(6):515. doi:10.1001/jama.1980.03300320013006
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.